Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CASI Pharmaceuticals ( (CASI) ) has provided an update.
On September 26, 2025, CASI Pharmaceuticals announced the appointment of James Huang as an Independent Director to its Board, effective October 1, 2025. Huang, with over 35 years of experience in the biotech industry, is expected to enhance CASI’s development program for CID-103, an anti-CD38 monoclonal antibody. This strategic appointment aligns with CASI’s focus on advancing its clinical development in autoimmune diseases and organ transplant rejection, marking a pivotal chapter in its U.S.-centric growth strategy. Additionally, Panacea Venture, where Huang is a managing partner, plans to acquire up to 1.5 million shares of CASI, indicating strong stakeholder confidence.
The most recent analyst rating on (CASI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
CASI Pharmaceuticals’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and high leverage. While technical analysis shows some positive momentum, poor valuation metrics due to significant losses further drag down the score.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for organ transplant rejection and autoimmune diseases. The company is actively working on CID-103, an anti-CD38 monoclonal antibody, which is in clinical trials for immune thrombocytopenic purpura and has received FDA clearance for trials in renal allograft antibody-mediated rejection.
Average Trading Volume: 1,230,867
Technical Sentiment Signal: Sell
Current Market Cap: $24.48M
For an in-depth examination of CASI stock, go to TipRanks’ Overview page.